Cargando…

Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan

BACKGROUND: There are a few reports on antibody responses after a two-dose BNT162b2 vaccination in non-epidemic areas. We evaluated this phenomenon. METHODS: A total of 344 healthcare workers were vaccinated, and the serum anti-receptor-binding domain (RBD) antibody concentrations before and after t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mokuda, Sho, Kawanishi, Namiki, Kuroshima, Shintaro, Kono, Junko, Nakayama, Hirofumi, Mieno, Hiroshi, Kawamoto, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Short communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173831/ https://www.ncbi.nlm.nih.gov/pubmed/35692460 http://dx.doi.org/10.1016/j.jvacx.2022.100173

Ejemplares similares

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Adverse events after BNT162b2 mRNA COVID-19 vaccination in health care workers and medical students in Japan
por: Namiki, Takahiro, et al.
Publicado: (2022)

Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine
por: Ciabattini, Annalisa, et al.
Publicado: (2023)

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
por: Nishiguchi, Yamato, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Rapid Progression of Polypoidal Choroidal Vasculopathy following Third BNT162b2 mRNA Vaccination
por: Sasajima, Hirofumi, et al.
Publicado: (2022)

Nonepisodic Angioedema with Eosinophilia Following Receipt of the BNT162b2 mRNA COVID-19 Vaccine
por: Koda, Tamaki, et al.
Publicado: (2023)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

N(1)-methylpseudouridine-incorporated mRNA enhances exogenous protein expression and suppresses immunogenicity in primary human fibroblast-like synoviocytes
por: Mokuda, Sho, et al.
Publicado: (2022)

Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan
por: Sanada, Takahiro, et al.
Publicado: (2023)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan
por: Kageyama, Takahiro, et al.
Publicado: (2021)

Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G
por: Hibino, Makoto, et al.
Publicado: (2021)

Markers of Memory CD8 T Cells Depicting the Effect of the BNT162b2 mRNA COVID-19 Vaccine in Japan
por: Kondo, Hiroyuki, et al.
Publicado: (2022)

Antibody responses to BNT162b2 mRNA COVID-19 vaccine in healthcare workers and patients with urological diseases in Japan
por: Hatakeyama, S., et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients
por: Hamaya, Tomoko, et al.
Publicado: (2022)

Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer’s BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study
por: Iwamoto, Momoko, et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan
por: Naito, Toshio, et al.
Publicado: (2021)

Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults
por: San Segundo, David, et al.
Publicado: (2021)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination: A case report()
por: Yamada, Maaya, et al.
Publicado: (2022)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Silvestris, Nicola
Publicado: (2021)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination
por: Lin, Ting-Yu, et al.
Publicado: (2022)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jo313on4vk24gfjofs85tv9a1u